AVANT to Present at the Roth Capital Partners New York Conference.NEEDHAM, Mass. -- AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) today announced that Dr. Una S. Ryan, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of AVANT Immunotherapeutics Inc., will present at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, New York Conference at the St. Regis Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. on Tuesday, September 14th at 9:00 a.m., EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . A live Web cast of the 30-minute presentation will be available online via the Investor Information area of AVANT's Web site at http://www.avantimmune.com and at http://wsw.com/webcast/roth4/avan. An archive of the Web cast will be available via AVANT's Web site for 90 days following the event. AVANT Immunotherapeutics Inc. discovers, develops and sells innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. The company has developed a broad, well-staged pipeline of vaccines and therapeutics for large, high-value, under-served markets. Six of AVANT's products are in clinical development. These include an oral human rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccine which gained its first marketing approval in Mexico in July 2004, a treatment to reduce complement-mediated tissue damage associated with cardiac by-pass surgery and a novel vaccine for cholesterol management. AVANT has also assembled a technology platform that enables the creation of rapid-protecting, single-dose, oral vaccines that remain stable without refrigeration refrigeration, process for drawing heat from substances to lower their temperature, often for purposes of preservation. Refrigeration in its modern, portable form also depends on insulating materials that are thin yet effective. . The company is developing applications of this vaccine technology in four areas: biodefense, travelers' vaccines, global health needs and human food safety. AVANT's goal is to demonstrate proof-of-concept for its products before leveraging further development through both traditional pharmaceutical partnerships and collaborations with governmental and other organizations. Additional information on AVANT Immunotherapeutics Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion